Home / TRAILR1/TNFRSF10A / Human TRAILR1/TNFRSF10A Antibody

Human TRAILR1/TNFRSF10A Antibody

Catalog #: AF347
38 Citations 1 Review Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
AF347
AF347-SP
Detection of Human TRAIL R1/TNFRSF10A by Western Blot.
4 Images
Product Details
Citations (38)
FAQs
Supplemental Products
Reviews (1)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human TRAILR1/TNFRSF10A Antibody Summary

Species Reactivity
Human
Specificity
Detects human TRAIL R1/TNFRSF10A in direct ELISAs and Western blots. In Western blots, approximately 10% cross-reactivity with recombinant human (rh) TRAIL R2 is observed and less than 1% cross-reactivity with rhTRAIL R3 and rhTRAIL R4 is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRAIL R1/TNFRSF10A
Ala24-Asn239
Accession # AAC51226
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
See below
Immunohistochemistry
5-15 µg/mL
See below
Neutralization
Measured by its ability to neutralize TRAIL R1/TNFRSF10A-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND50) is typically 0.02-0.055 µg/mL in the presence of 10 ng/mL Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera, 12 ng/mL Recombinant Human TRAIL/TNFSF10, a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody, and 1 µg/mL actinomycin D.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Human TRAIL R1/TNFRSF10A antibody by Western Blot. View Larger

Detection of Human TRAIL R1/TNFRSF10A by Western Blot. Western blot shows lysates of TF-1 human erythroleukemic cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R1/TNFRSF10A at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions.

Neutralization TRAIL R1/TNFRSF10A Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R1/TNFRSF10A Antibody. View Larger

TRAIL R1/TNFRSF10A Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R1/TNFRSF10A Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera (Catalog # 347-DR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R1/ TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347). The ND50 is typically 0.02-0.055 µg/mL.

Immunohistochemistry TRAIL R1/TNFRSF10A antibody in Human Brain by Immunohistochemistry (IHC-P). View Larger

TRAIL R1/TNFRSF10A in Human Brain. TRAIL R1/TNFRSF10A was detected in immersion fixed paraffin-embedded sections of human brain using Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347) at 10 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in neurons. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Western Blot Detection of Human TRAILR1/TNFRSF10A by Western Blot View Larger

Detection of Human TRAILR1/TNFRSF10A by Western Blot B3GNT2 disrupts ligand–receptor interactions between tumor and T cells.a Cell survival against T cell cytotoxicity (top) and T cell IFN gamma secretion (bottom) in A375 cells overexpressing B3GNT2 or GFP that have been treated with different concentrations of kifunensine. Kifunensine was used to pretreat A375 cells and was present during co-culture with T cells at E:T ratio of 3. Kifunensine-treated cells that were co-cultured with ESO T cells were compared to kifunensine-treated cells cultured in parallel without T cells to determine percent survival. N = 6. Two-tailed t tests were performed. b Tomato lectin IP of A375 cells overexpressing GFP or B3GNT2 followed by western blot for different B3GNT2 target proteins. 2% of the input and no lectin IP controls are shown. Data are representative of two independent experiments. c Western blots of A375 cells overexpressing B3GNT2 or GFP that were treated with kifunensine (KIF) or benzyl-2-acetamido-2-deoxy-alpha -D-galactopyranoside (BAG) to remove N- or O-glycosylation respectively. Data are representative of two independent experiments. d Histograms (top) and corresponding median fluorescence intensity (MFI; bottom) showing binding of recombinant T cell proteins to A375 cells measured by flow cytometry. A375 cells were overexpressing GFP or B3GNT2 and treated with KIF or BAG. N = 3. Two-tailed t tests were performed. e Schematic showing the tumor cell surface ligands and receptors modified by B3GNT2 to disrupt interactions with T cells that mediate cytotoxicity. All values are mean ± s.e.m. ns not significant. Source data are provided in Source Data 4. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35338135), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRAILR1/TNFRSF10A

Human TRAIL R1, also called DR4, is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL RI is referred to as TNFRSF10A. TRAIL R1 cDNA encodes a 468 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among the TNF receptor family proteins, TRAIL R1 is most closely related to TRAIL R2/DR5, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R1 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R1/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R1, an additional TRAIL R2/DR5, which tranduces apoptosis signal, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

References
  1. Pan, G. et al. (1997) Science 276:111.
  2. Golstein, P. (1997) Curr. Biol. 7:R750.
Long Name
TRAIL Receptor 1
Entrez Gene IDs
8797 (Human)
Alternate Names
APO2; CD261 antigen; CD261; cytotoxic TRAIL receptor; Death receptor 4; DR4 TRAIL receptor 1; DR4; TNF-related apoptosis inducing ligand receptor 1; TNF-related apoptosis-inducing ligand receptor 1; TNFRSF10A; TRAIL R1; TRAILR1; TRAIL-R1; TRAILR-1; TRAILR1MGC9365; tumor necrosis factor receptor superfamily member 10A; tumor necrosis factor receptor superfamily, member 10a

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human TRAILR1/TNFRSF10A Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

38 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells
    Authors: Jun-Jie Chen, H.-C. Jennifer Shen, Leslie A. Rivera Rosado, Yaqin Zhang, Xu Di, Baolin Zhang
    Oncotarget
  2. Limiting glutamine utilization activates a GCN2/TRAIL-R2/Caspase-8 apoptotic pathway in glutamine-addicted tumor cells
    Authors: R Yerbes, R Mora-Molin, FJ Fernández-, L Hiraldo, A López-Riva, C Palacios
    Cell Death & Disease, 2022-10-27;13(10):906.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  3. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
    Authors: J Joung, PC Kirchgatte, A Singh, JH Cho, SP Nety, RC Larson, RK Macrae, R Deasy, YY Tseng, MV Maus, F Zhang
    Nature Communications, 2022-03-25;13(1):1606.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  4. Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models
    Authors: M Kopczynski, M Statkiewic, M Cybulska, U Kuklinska, K Unrug-Biel, Z Sandowska-, A Grochowska, M Gajewska, M Kulecka, J Ostrowski, M Mikula
    International Journal of Molecular Sciences, 2021-03-19;22(6):.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  5. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy
    Authors: JD Yoo, SM Bae, J Seo, IS Jeon, SMP Vadevoo, SY Kim, IS Kim, B Lee, S Kim
    Sci Rep, 2020-11-17;10(1):19997.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. PIM kinases mediate resistance of glioblastoma cells to TRAIL by a p62/SQSTM1-dependent mechanism
    Authors: S Serrano-Sa, C Palacios, D Delgado-Be, L López-Jimé, A Garcia-Dia, Y Soto-Serra, JI Casal, RA Bartolomé, JL Fernández-, A López-Riva, FJ Oliver
    Cell Death Dis, 2019-01-18;10(2):51.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  7. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells
    Authors: Y Shlyakhtin, V Pavet, H Gronemeyer
    Cell Death Dis, 2017-08-31;8(8):e3025.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  8. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
    Authors: V Liapis, A Zysk, M DeNichilo, I Zinonos, S Hay, V Panagopoul, A Shoubridge, C Difelice, V Ponomarev, W Ingman, GJ Atkins, DM Findlay, ACW Zannettino, A Evdokiou
    Cancer Med, 2017-08-10;0(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  9. Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis
    Authors: C Liang, Y Xu, G Li, T Zhao, F Xia, G Li, D Zhang, J Wu
    Onco Targets Ther, 2017-01-18;10(0):417-428.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  10. Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs).
    Authors: Zinonos I, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ponomarev V, Ingman W, Atkins G, Findlay D, Zannettino A, Evdokiou A
    Anticancer Res, 2014-12-01;34(12):7007-20.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  11. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
    Authors: Elias A, Siegelin MD, Steinmuller A, von Deimling A, Lass U, Korn B, Mueller W
    Clin. Cancer Res., 2009-08-25;15(17):5457-65.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  12. Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells.
    Authors: Park SJ, Sohn HY, Yoon J, Park SI
    Cell. Signal., 2009-05-24;21(10):1495-503.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  13. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2.
    Authors: Siegelin MD, Gaiser T, Habel A, Siegelin Y
    Cancer Lett., 2009-04-26;283(2):230-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Western Blot
  14. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Authors: Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH
    Biochem. Pharmacol., 2009-01-24;77(8):1328-36.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  15. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
    Authors: Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M
    Int. J. Oncol., 2008-08-01;33(2):381-8.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  16. TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
    Authors: Wu CH, Kao CH, Safa AR
    Hum. Gene Ther., 2008-07-01;19(7):731-43.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  17. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
    Authors: Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS
    Cancer Res., 2008-01-01;68(1):266-75.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  18. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
    Authors: Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M
    Int. J. Oncol., 2007-12-01;31(6):1391-402.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  19. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
    Authors: Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, Singh J, Xia G, Broek D, Schonthal AH, Gill PS
    Int. J. Cancer, 2006-09-15;119(6):1236-48.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  20. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Authors: Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR
    Biochem. Pharmacol., 2006-05-04;72(3):293-307.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry, Neutralization
  21. Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
    Authors: Lane D, Cote M, Grondin R, Couture MC, Piche A
    Mol. Cancer Ther., 2006-03-01;5(3):509-21.
    Species: Human
    Sample Types: Whole Cells
    Applications: Western Blot
  22. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
    Authors: Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL
    Biochem. Biophys. Res. Commun., 2005-07-22;333(1):42-50.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  23. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.
    Authors: Morel J, Audo R, Hahne M, Combe B
    J. Biol. Chem., 2005-01-31;280(16):15709-18.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  24. Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death.
    Authors: Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A, Colombo A, Parati E, Peschle C, De Maria R
    J. Exp. Med., 2004-11-15;200(10):1257-66.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  25. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
    Authors: Chopin V, Slomianny C, Hondermarck H, Le Bourhis X
    Exp. Cell Res., 2004-08-15;298(2):560-73.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  26. TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia.
    Authors: Ryan LA, Peng H, Erichsen DA, Huang Y, Persidsky Y, Zhou Y, Gendelman HE, Zheng J
    J. Neuroimmunol., 2004-03-01;148(1):127-39.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  27. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
    Authors: Ruiz de Almodovar C, Ruiz-Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A
    J. Biol. Chem., 2003-11-17;279(6):4093-101.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  28. Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction.
    Authors: Nakajima H, Yanase N, Oshima K, Sasame A, Fukazawa S, Takata R, Mukai K, Yamashina A, Mizuguchi J
    Jpn Heart J, 2003-11-01;44(6):833-44.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  29. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
    Authors: Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G
    J. Leukoc. Biol., 2003-08-01;74(2):223-32.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  30. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
    Authors: Mouzakiti A, Packham G
    Br. J. Haematol., 2003-07-01;122(1):61-9.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  31. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
    Authors: Voelkel-Johnson C
    Cancer Biol. Ther., 2003-05-01;2(3):283-90.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  32. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
    Authors: Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P
    Circ. Res., 2003-03-20;92(7):732-40.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  33. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
    Authors: Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K
    Oncogene, 2003-03-20;22(11):1653-62.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  34. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
    Authors: Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC
    Oncogene, 2002-08-22;21(37):5673-83.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  35. Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells.
    Authors: Hueber A, Aduckathil S, Kociok N, Welsandt G, Dinslage S, Kirchhof B, Esser PJ
    Chin. Med. J., 2002-06-20;240(7):551-6.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  36. Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
    Authors: Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR
    Cell Death Differ., 2002-03-01;9(3):274-86.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  37. TRAIL induces apoptosis in oral squamous carcinoma cells: a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5
    Authors: Jun-jie Chen, Constantinos M. Mikelis, Yaqin Zhang, J. Silvio Gutkind, Baolin Zhang
    Oncotarget
  38. TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis
    Authors: Reema Baskar, Harris G Fienberg, Zumana Khair, Patricia Favaro, Sam Kimmey, Douglas R Green et al.
    Life Science Alliance

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human TRAILR1/TNFRSF10A Antibody

Average Rating: 4 (Based on 1 Review)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human TRAILR1/TNFRSF10A Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human TRAIL R1/TNFRSF10A Antibody
By Anonymous on 07/23/2018
Application: WB Sample Tested: HT-29 human colon adenocarcinoma cell line,MCF-7 human breast cancer cell line Species: Human

Total cell lysates from HT29 and MCF-7 were subjected to western blot. PVDF membrane were probed with 1 mm/ml Human DR4 Antibody (AF347). A specific band was detected for DR4 at approximately 55 kDa. This experiment was conducted under reducing conditions.

Western Blot Human TRAIL R1/TNFRSF10A Antibody AF347